Medicare Part D Research Highlights and Policy Updates, 2013: Impact and Insights

Clinical Therapeutics

Volumn 35, Issue 4, 2013, Pages 402-412

  Stubbings, JoAnn ^a   Lau, Denys T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Expenditures; Medicare Part D; Outcomes; Policymaking; Research

Indexed keywords

ARTICLE; DATA BASE; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFORMATION PROCESSING; MEDICARE; STANDARDIZATION;

DRUG COSTS; DRUG UTILIZATION REVIEW; HEALTH POLICY; HEALTH SERVICES RESEARCH; MEDICARE PART D; UNITED STATES;

EID: 84876331532     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.02.024     Document Type: Article

References (45)

1. Announcement of Calendar Year (CY) 2013 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. Memo to All Medicare Advantage organizations, prescription drug plan sponsors, and other interested parties, April 2, 2012 US Dept of Health and Human Services, Centers for Medicare & Medicaid Services (CMS), Accessed January 12, 2013. http://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/downloads/Announcement2013.pdf.
2. Tudor CG. State of Part D: 2006-2012. Presented at:CMS2012 Medicare Prescription Drug Benefit Symposium, March 20-21, 2012, Hunt Valley, Md.
3. Offsetting effects of prescription drug use on Medicare's spending for other health care services. 43741, November 29, 2012 Congressional Budget Office, Accessed January 12, 2013. http://www.cbo.gov/publication/43741.
4. Lau D.T., Stubbings J.A. Medicare Part D research and policy highlights, 2012: Impact and insights. Clin Ther 2012, 34:904-914.
5. Zhou C., Zhang Y. The vast majority of Medicare Part D beneficiaries still don't choose the cheapest plans that meet their medication needs. Health Aff (Millwood) 2012, 31:2259-2265.
6. Howell B.L., Powers C.A., Weinhandl E.D., et al. Sources of drug coverage among Medicare beneficiaries with ESRD. J Am Soc Nephrol 2012, 23:959-965.
7. Butler M.G., Farley J.F., Sleath B.L., et al. Medicare part D information seeking: the role of recognition of need and patient activation. Res Social Adm Pharm 2012, 8:433-442.
8. Barnes A.J., Hanoch Y., Wood S., et al. One fish, two fish, red fish, blue fish: effects of price frames, brand names, and choice set size on Medicare Part D insurance plan decisions. Med Care Res Rev 2012, 69:460-473.
9. Kling J.R., Mullainathan S., Shafir E., et al. Comparison friction: experimental evidence from Medicare drug plans. Q J Econ 2012, 127:199-235.
10. Polinski J.M., Brookhart M.A., Glynn R.J., Schneeweiss S. Medicare Part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. J Clin Psychopharmacol 2012, 32:3-10.
11. Cheng L.I., Rascati K.L. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008. Arthritis Care Res (Hoboken) 2012, 64:1423-1429.
12. Donohue J.M., Marcum Z.A., Gellad W.F., et al. Medicare Part D and potentially inappropriate medication use in the elderly. Am J Manag Care 2012, 18:e315-e322.
13. Ong M.K., Xu H., Zhang L., et al. Effect of Medicare Part D benzodiazepine exclusion on psychotropic use in benzodiazepine users. J Am Geriatr Soc 2012, 60:1292-1297.
14. Ong M.K., Zhang L., Xu H., et al. Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders. Psychiatr Serv 2012, 63:637-642.
15. Li P., McElligott S., Bergquist H., et al. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med 2012, 156:776-784. W-263-W-269.
16. Polinski J.M., Shrank W.H., Glynn R.J., et al. Beneficiaries with cardiovascular disease and the Part D coverage gap. Circ Cardiovasc Qual Outcomes 2012, 5:387-395.
17. Baik S.H., Rollman B.L., Reynolds C.F., et al. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure. J Ment Health Policy Econ 2012, 15:105-118.
18. Zhang Y., Baik S.H., Zhou L., et al. Effects of Medicare Part D coverage gap on medication and medical treatment among elderly beneficiaries with depression. Arch Gen Psychiatry 2012, 69:672-679.
19. Page R.L., Ghushchyan V., Allen R.R., et al. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drug Healthc Patient Saf 2012, 4:67-74.
20. Kautter J., Ingber M., Pope G.C., Freeman S. Improvements in Medicare Part D risk adjustment: beneficiary access and payment accuracy. Med Care 2012, 50:1102-1108.
21. Jung K., McBean A.M., Kim J.A. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs. J Manag Care Pharm 2012, 18:106-115.
22. Stuart B., Yin X., Davidoff A., et al. Impact of Part D low-income subsidies on medication patterns for Medicare beneficiaries with diabetes. Med Care 2012, 50:913-919.
23. Priest J., Buikema A., Engel-Nitz N.M., et al. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy. Popul Health Manag 2012, 15:101-112.
24. Hoadley J.F., Merrell K., Hargrave E., Summer L. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions. Health Aff (Millwood) 2012, 31:2266-2275.
25. Polinski J.M., Shrank W.H., Glynn R.J., et al. Association between the Part D coverage gap and adverse health outcomes. J Am Geriatr Soc 2012, 60:1408-1417.
26. Polinski J.M., Schneeweiss S., Glynn R.J., et al. Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Pharmacoepidemiol Drug Saf 2012, 21(Suppl 2):90-98.
27. Williams J., Steers W.N., Ettner S.L., et al. Cost-related nonadherence by medication type among Medicare Part D Beneficiaries With Diabetes. Med Care 2012 Sep 29, [Epub ahead of print].
28. Frankenfield D.L., Weinhandl E.D., Powers C.A., et al. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. Am J Kidney Dis 2012, 59:670-681.
29. Holmes H.M., Luo R., Hanlon J.T., et al. Ethnic disparities in adherence to antihypertensive medications of Medicare Part D beneficiaries. J Am Geriatr Soc 2012, 60:1298-1303.
30. Piccini J.P., Mi X., DeWald T.A., et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm 2012, 9:1403-1408.
31. Zhang Y., Steinman M.A., Kaplan C.M., et al. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med 2012, 1-7.
32. Donohue J.M., Morden N.E., Gellad W.F., et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med 2012, 366:530-538.
33. Roth G.A., Morden N.E., Zhou W., et al. Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. Circ Cardiovasc Qual Outcomes 2012, 5:103-112.
34. Baillargeon J., Holmes H.M., Lin Y.L., et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012, 125:183-189.
35. Yun H., Curtis J.R., Saag K., et al. Generic alendronate use among Medicare beneficiaries: are part d data complete?. Pharmacoepidemiol Drug Saf 2013, 22:55-63.
36. Hill S.C., Zuvekas S.H., Zodet M.W. Validity of reported Medicare Part D enrollment in the medical expenditure panel survey. Med Care Res Rev 2012, 69:737-750.
37. Shoemaker J.S., Davidoff A.J., Stuart B., et al. Eligibility and take-up of the Medicare Part D low-income subsidy. Inquiry 2012, 49:214-230.
38. Medicare program; changes to the Medicare Advantage and the Medicare prescription drug benefit programs for contract year 2013 and other changes. Final rule with comment period. Fed Regist 2012, 77:22072-22175. US Dept of Health and Human Services, Centers for Medicare & Medicaid Services, PMID: 22606715.
39. Transition to Part D coverage of benzodiazepines and barbiturates beginning in 2013. Memo to Part D Sponsors October 2, 2012, US Dept of Health and Human Services, Centers for Medicare & Medicaid Services.
40. Zhang Y., Gellad W.F., Zhou L., et al. Access to and use of $4 generic programs in Medicare. J Gen Intern Med 2012, 27:1251-1257.
41. CY 2013 medication therapy management program guidance and submission instructions. Memo to All Part D sponsors and capitated financial alignment demonstration contracts April 10, 2012, US Dept of Health and Human Services, Centers for Medicare & Medicaid Services.
42. Branham A.R., Katz A.J., Moose J.S., et al. Retrospective analysis of estimated cost avoidance following pharmacist-provided medication therapy management services. J Pharma Pract 2012 Nov 25, [Epub ahead of print].
43. Moczygemba L.R., Brannier J.C., Gabrillo E.R. Outcomes of a Medicare Part D telephone medication therapy management program. J Am Pharm Assoc 2012, 52:e144-e152.
44. Medicare Part D instances of questionable access to prescription drugs. GAO-11-699, September 2011 US Government Accountability Office, Accessed January 12, 2013. http://www.gao.gov/new.items/d11699.pdf.
45. Bazalo G., Weiss R.C. Impact of final short-fill rule on Medicare Part D costs and long term care pharmacy dispensing. Consult Pharm 2012, 27:269-273.